Trodelvy 180 mg Injection(Sacituzumab govitecan-hziy) injection is a Trop-2-directed ADC and topoisomerase inhibitor conjugate approved to treat adults with:
Unresectable locally advanced or mTNBC (metastatic triple-negative breast cancer) who have previously been treated with two or more systemic therapies, at least one of them for metastatic disease.
Unresectable locally advanced or metastatic hormone receptor (HR)- positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have been treated with endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.
Locally advanced or metastatic urothelial cancer (mUC) who have previously been treated with platinum-containing chemo and either PD-1 (which stands for programmed death receptor-1) or PDL1 (which stands for programmed death-ligand 1 inhibitor).